

Inserm Workshop 278

Epigenetics in health: a focus on rare diseases



REGISTRATION DEADLINE: January 12, 2024

ORGANIZERS: Frédérique MAGDINIER (Inserm U1251, Marseille), Slimane AIT-SI-ALI and Guillaume VELASCO (CNRS UMR 7216, Paris)

AIMS: Epigenetic processes, frequently disrupted in diseases, are now a key focus in modern medicine due to their potential reversibility and possible therapeutic interventions. Participants will acquire theoretical and technical knowledge on how epigenetics alterations impact human health and contribute to diseases.



PHASE I – CRITICAL ASSESSMENT

April 2-4, 2024 in Bordeaux

EPIGENETIC PROCESSES; STATE OF THE ART

Adrian BIRD (University of Edinburgh, GBR), Claire ROUGEULLE (CNRS UMR 7216, FRA) and Deborah BOURC'HIS (Institut Curie, FRA)

EPIGENETICS IN HEALTH


Anne GABORY (INRA, FRA), Yuval DOR (Institute for Biomedical Res, ISR), Eric PASMANT (Institut Cochin, FRA) and Michael ROBSON (Max Planck Institute for Molecular Genetics, DEU)

EPIGENETICS AND RARE DISEASES

Michael S. KOBOR (BC Children's Hospital, CAN), Maria J. BARRERO (National Institute of Health Carlos III, ESP), Matthieu DEFRANCE (Interuniversity Institute of Bioinformatics Brussels, BEL), Maria MATARAZZO (IGB-CNR, ITA) and Chiara LANZUOLO (San Raffaele, ITA)

EPIIDRUGS AND DRUG DESIGN

Maria BERDASCO (Bellvitge Biomedical Research Institute), Paola ARIMONDO (Institut Pasteur, FRA) and Kyle BIGGAR (Carleton University, CAN)



PHASE II – TECHNICAL WORKSHOP

May 14-16, 2024 in Paris

The objectives of the "epigenetics in health" practical workshop are to provide participants with theoretical insights on DNA methylation and its experimental methods of exploration. This interactive session will showcase tools for analyzing and validating of DNA methylation data focusing on Illumina's EPIC chip technology which is the most widely used in the field of rare diseases, and pyrosequencing. Prior to the workshop, participants will receive a questionnaire to tailor the training to their specific scientific interests especially in data analysis.

SELECTION: 10 trainees will be selected among Phase I participants

Information and registration:
<https://ateliersinserm.dakini-pco.com>